Radek Spisek, SOTIO CEO (Cellestia)

A Czech biotech bets big on ris­ing ADC play­er LegoChem as part of li­cens­ing pact aimed at sol­id tu­mors

Czech biotech So­tio will pay $29.5 mil­lion up­front and in near-term mile­stones with a po­ten­tial $1.03 bil­lion in down­stream biobucks to li­cense five an­ti­body-drug con­ju­gate pro­grams from LegoChem Bio­sciences, the part­ners an­nounced Tues­day.

De­tails on the col­lab­o­ra­tion are slim, but So­tio did say the pro­grams would tar­get dis­tinct anti­gens in sol­id tu­mors. The pact will lever­age So­tio’s an­ti­body li­brary with LegoChem’s pay­load-link­er tech­nol­o­gy in what the part­ners hope will prove a po­tent com­bi­na­tion against can­cer.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.